

<b>Board Diversity Matrix for</b>				
<b>As of</b>				
Total Number of Directors				
<b>Part I: Gender Identity</b>	<b>Female</b>	<b>Male</b>	<b>Non-Binary</b>	<b>Did Not Disclose Gender</b>
Directors				
<b>Part II: Demographic Background</b>				
African American or Black				
Alaskan Native or American Indian				
Asian				
Hispanic or Latinx				
Native Hawaiian or Pacific Islander				
White				
Two or More Races or Ethnicities				
LGBTQ+				
Did Not Disclose Demographic Background				

As of December 31, 2023, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) was assembled with a focus on attaining a Board comprised of people with substantial experience in bioscience, the pharmaceutical or diagnostic industry, corporate management, and finance. The Board believes that this interdisciplinary approach best suits the Company’s needs at this particular stage, as the Company works to develop and commercialize diagnostic tests. While the Board has not yet identified an appropriate candidate as of December 31, 2023, the Board intends to cause the Company to comply with the Nasdaq diversity rules and any applicable California diversity requirements by adding qualified women and qualified persons from underrepresented communities to the Board at a later date.